Zenas BioPharma

Zenas BioPharma, founded and initially funded by Tellus BioVentures, LLC and Fairmount Funds Management LLC, is a multinational (China-U.S.-based) biopharmaceutical company dedicated to developing and delivering immunotherapies that improve the lives of patients with autoimmune and rare diseases in China and globally. The company’s lead candidate, ZB001, has the potential to be a leading treatment for thyroid eye disease in China. Zenas is rapidly advancing a deep pipeline of innovative therapies and continues to grow through successful business development strategies. Zenas BioPharma’s experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies that improve the lives of those facing autoimmune and rare diseases.